DANAHER CORP /DE/ Q4 FY2024 earnings call

Management Statement and Operational Highlights

• Year-End Performance: Finished 2024 strong with better-than-anticipated core revenue in all segments. Bioprocessing and Life Sciences instruments showed positive momentum. Disciplined execution drove solid cash flow and operating profit margin expansion.
• 2024 Financials: Sales $23.9 billion, core revenue declined 1.5%. Adjusted operating profit margin 28.6%, adjusted diluted net earnings per share $7.48, free cash flow $5.3 billion.
• Fourth Quarter 2024 Results: Sales $6.5 billion, 1% core revenue growth. Gross profit margin 59.5%, adjusted operating profit margin 29.6%, adjusted diluted net earnings per share $2.14, free cash flow $1.5 billion.
• Innovation: Launched several groundbreaking technologies, e.g., Cytiva's Sefia cell therapy manufacturing platform, Beckman Coulter Life Sciences' Cydem VT Automated Cell Culture System, Beckman Coulter Diagnostics' DxI 9000 advancements.

Segment Performance

• Biotechnology Segment: Core revenue increased high-single-digits year-over-year. Bioprocessing up high-single-digits, discovery and medical up low-double-digits. Orders grew high-single-digits sequentially for six consecutive quarters.
• Life Sciences Segment: Core revenue increased 1%. Instrument business slightly up, genomics consumables declined. For 2025, expected low-single-digit growth for tools, Pall and Genomics down.
• Diagnostics Segment: Core revenue decreased 2%. Clinical diagnostics had low-single-digit growth (Biosystems nearly 10% growth), Beckman Coulter Diagnostics flat with China impact, Cepheid had mid-teens growth in non-respiratory reagent portfolio.

Guidance

• 2025 Full-Year: Anticipates core revenue growth ~3%, ~2% revenue headwind from U.S. dollar strength. Adjusted operating profit margin ~28.5%. First quarter expected core revenue decline in low-single-digit range, adjusted operating profit margin ~26.5%.
• Life Sciences 2025: Expected low-single-digit growth for tools, Pall and Genomics down. Phasing: Q1 down mid-single digits, Q2 and beyond expected to improve.
• Biotechnology 2025: Expected 6%-7% core growth, steady throughout the year.

Risks

• Export Controls: Recent export control headlines surrounding flow cytometry and mass spec, but currently not meaningfully impacting Danaher as portfolio is positioned differently. Regular review and adjustment of export controls possible, but no significant impact seen to date.
• Market Volatility: External factors like U.S. academic government funding changes, China market challenges (volume-based procurement, market conditions), and respiratory season impacts on diagnostics could affect performance.

Question and Answer

• Q: Digging into Life Sciences 2025 guide pacing A: Life Sciences has external environment noise, expecting low-single-digit growth for tools, Pall and Genomics down. Phasing: Q1 down mid-single digits, Q2 and beyond expected to improve.
• Q: Diagnostics segment shortfall vs expectations A: VBP in China $150M vs previous $50M, respiratory season impact. Respiratory revenue expected $1.7B as endemic rate, not $2B seen in last two years.
• Q: Bioprocessing order growth linkage to forward growth A: Strong order growth in bioprocessing (six consecutive high single-digit orders growth), sets up well for 2025, with consumables strong but instrumentation still subdued but improving.
• Q: AI application in R&D A: AI applied to accelerate R&D, assay development, and decision support systems, reducing cycle times.
• Q: Abcam and Aldevron deal model A: Abcam tracking close, Aldevron behind due to genomics end-markets taking longer to round out.
• Q: Capital deployment and M&A criteria A: Q1 and Q4 share repurchase activity, M&A criteria include right end-market, secular growth drivers, liking the asset/company, and valuation framework.
• Q: Export controls impact and risk A: Current export controls not meaningfully impacting Danaher, portfolio positioned differently, regular review process expected.
• Q: Bioprocessing recovery pace and seasonality A: Recovery underway, 6%-7% core growth expected quarterly. Seasonality: Q1 light, Q2 up, Q3 down, Q4 step-up.